Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over labelling issue

The reason for the recall of lipid-lowering Simvastatin tablets is "Labeling; incorrect or missing lot and/or exp date; some bottles labelled with lot number 05318054B instead of 05318034B," Aurobindo Pharma added.

New Delhi: The US arm of drug major Aurobindo Pharma is recalling 2,352 bottles of lipid-lowering Simvastatin tablets from the American market, the latest enforcement report of the US health regulator said.

Aurobindo Pharma USA Inc is recalling 2,352/1,000 count bottles of Simvastatin tablets USP 40 mg manufactured by Aurolife Pharma LLC, the United States Food and Drug Administration (USFDA) said in its Enforcement Report.

The voluntary ongoing nationwide recall is a class III recall, it added.

Read Also: Aurobindo Pharma, Shanghai LongJin sign deal to form JV in China

The product was distributed nationwide by three major distributors who may have further distributed the product, the report said.

The reason for the recall is "Labeling; incorrect or missing lot and/or exp date; some bottles labelled with lot number 05318054B instead of 05318034B," it added.

As per the USFDA, a class III recall is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences".

Read Also: 2 dead, 1 injured after fire engulfed Aurobindo Pharma power plant in Andhra Pradesh